Company profile
ImaginAb company profile
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
Business identity
- Website
- http://imaginab.com
- Contact email
- [email protected]
- Phone number
- 310-645-1211
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $1M-$10M
- Founded
- 2007-01-01, Year
Headquarters
- Headquarters
- Germantown, Wisconsin, United States
- Postal code
- 90301
- Country code
- US
- Continent
- North America